| Biotech Stock Alert; Aethlon Medical (OTCBB: AEMD) Reports FDA Meeting Request ... - InvestorIdeas.com (press release) |
|
|
InvestorIdeas.com (press release) The Hemopurifier® is also uniquely suited to treat HCV-infected End-stage renal disease (ESRD) patients, whose condition limits their ability to be treated with HCV-SOC. The incidence of HCV infection in ESRD patients is approximately 100-1000 times |